Center for Biosanitary Studies (CEB) shared a post on LinkedIn:
“New study on thyroid cancer (ATC) and adrenocortical carcinoma (ACC)․
In phase II of the CABATEN/GETNE – T1914 project, led by our former professor Enrique Grande and in which other alumni from our Master’s in Molecular Oncology have participated, it has been shown that the combination of cabozantinib plus atezolizumab offers a very promising safety and efficacy profile in adrenocortical carcinoma (ACC) and anaplastic thyroid cancer (ATC), achieving lasting responses of more than one year in some patients. More information.
At CEB, we believe that research is essential to improve patient lives. Do you also want to collaborate in oncological research? Sign up now for the AI in Research courses and the monographic courses in Molecular Oncology! Visit us․”
Title: Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A multi-cohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
Authors: Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, Marta Benavent Viñuales, Rocio Garcia-Carbonero, Alex Teulé, Ana Custodio, Paula Jimenez-Fonseca, Carlos Lopez, Cinta Hierro, Alberto Carmona-Bayonas, Vicente Alonso, Marta Llanos, Isabel Sevilla, Alejandro Garcia-Alvarez, Teresa Alonso-Gordoa, Inmaculada Gallego Jiménez, Beatriz Antón-Pascual, Andrea Modrego Sánchez, Enrique Grande
Read the full article on Clinical Cancer Research.
More posts featuring CEB.